A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild‐to‐moderate asthma

BACKGROUND: GB001 is an oral antagonist of the prostaglandin D2 receptor that may inhibit recruitment and activation of airway eosinophils, reducing airway inflammation. OBJECTIVE: To assess GB001 safety, efficacy and pharmacokinetics from a Phase 2 study and explore the association between type 2 b...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortega, Hector, Fitzgerald, Mary, Raghupathi, Kartik, Tompkins, Cindy‐ann, Shen, Jinshan, Dittrich, Karen, Pattwell, Caroline, Singh, Dave
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027764/
https://www.ncbi.nlm.nih.gov/pubmed/31659803
http://dx.doi.org/10.1111/cea.13524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027764/
https://www.ncbi.nlm.nih.gov/pubmed/31659803
http://dx.doi.org/10.1111/cea.13524

Ejemplares similares